Routine

Dyslipidaemia management & statin therapy

lipids · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Assessment and treatment of elevated LDL and other lipids to reduce atherosclerotic cardiovascular risk, using risk stratification and statin-based therapy. Secondary and familial causes should be excluded first.

Red flags

  • Triglycerides >11 mmol/L (pancreatitis risk)
  • Features of familial hypercholesterolaemia
  • Muscle pain with marked CK rise (rhabdomyolysis)
  • New cardiovascular event on treatment
  • Unexplained transaminase elevation >3x upper limit

Assessment

Differential diagnosis

  • Familial hypercholesterolaemia
  • Secondary dyslipidaemia (hypothyroidism, diabetes, nephrotic, alcohol)
  • Familial combined hyperlipidaemia
  • Severe hypertriglyceridaemia
  • Metabolic syndrome

Investigations

  • Lipid profile (total, LDL, HDL, triglycerides, non-HDL)
  • Cardiovascular risk calculation (e.g. QRISK3)
  • TSH, HbA1c, renal and liver function
  • Lipoprotein(a) once in a lifetime
  • Baseline creatine kinase if muscle symptoms/risk

Management

  • Exclude and treat secondary causes before committing to lifelong therapy
  • Stratify risk: established cardiovascular disease, diabetes, CKD, FH, or calculated risk
  • Advise diet, weight, exercise, smoking cessation and alcohol moderation
  • Offer high-intensity statin for secondary prevention and high-risk primary prevention
  • Set goals: >=40% non-HDL reduction (primary) or lower absolute LDL targets in high-risk/secondary prevention
  • Check response and adherence at 2-3 months; uptitrate as needed
  • Add ezetimibe then PCSK9 inhibitor/inclisiran/bempedoic acid if targets unmet
  • Manage significant hypertriglyceridaemia (fibrate/icosapent ethyl) once LDL controlled
  • Monitor liver enzymes and manage statin intolerance with rechallenge/alternatives
  • Review cardiovascular risk periodically

Drugs & doses

Atorvastatin 20-80 mg or rosuvastatin 10-40 mg PO once daily
Ezetimibe 10 mg PO once daily
PCSK9 inhibitor (alirocumab/evolocumab) SC or inclisiran SC twice yearly
Icosapent ethyl 2 g PO twice daily for residual hypertriglyceridaemia
Fenofibrate 145 mg PO once daily for marked hypertriglyceridaemia

Disposition

Manage in primary care with risk-based follow-up; refer to lipid clinic for suspected FH, statin intolerance, or targets unmet on combination therapy.

Complications & pitfalls

  • Atherosclerotic cardiovascular disease
  • Acute pancreatitis (severe hypertriglyceridaemia)
  • Statin-associated muscle symptoms/rhabdomyolysis
  • Undertreatment of high-risk patients

Exam pearls

  • Lower LDL is better in high-risk patients; combine agents to reach target
  • Most statin muscle symptoms are not true myopathy; rechallenge or switch rather than abandon
  • Check lipoprotein(a) once as an independent residual risk marker
  • Very high triglycerides threaten the pancreas and need triglyceride-focused therapy first

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.